Cancer News and Research

Latest Cancer News and Research

Late-stage prostate tumors are driven by different hormonal pathway

UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.

26 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.

26 Jul 2011

Symposium papers highlight role of oxidative stress in cardiovascular disease

Recent years have seen major advances in understanding of the health effects of oxidative stress—including its potential to cause injury to the cardiovascular system. A series of expert updates on the role of oxidative stress in heart failure, atherosclerosis, and other cardiovascular diseases appears in a special symposium in the August issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

26 Jul 2011

New potential anti-tumor agents might effectively treat mesothelioma

Researchers from the lab of Antonio Giordano, M.D., Ph.D., the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, have identified new potential anti-tumor agents that might be effective in treating mesothelioma, one of the deadliest cancer tumors.

26 Jul 2011

New ATA guidelines on diagnosis and management of thyroid disease during pregnancy

Emerging data clarifying the risks of insufficient thyroid activity during pregnancy on the health of the mother and fetus, and on the future intellectual development of the child, have led to new clinical guidelines for diagnosing and managing thyroid disease during this critical period.

26 Jul 2011

Specific predictors can differentiate dying suddenly versus living through heart attack

Is it possible to predict whether someone is likely to survive or die suddenly from a heart attack? A new study by researchers at Wake Forest Baptist Medical Center has answered just that.

26 Jul 2011

Book on human papilloma virus

A pair of oncologists in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island recently co-authored a pocket-sized guide to the human papilloma virus (HPV) so physicians can make more accurate diagnosis and plan more effective treatment for women with the virus.

26 Jul 2011

Tumor marker, endoscopic ultrasound more likely to detect stage 1 pancreatic cancer

Researchers from New England report in a new study that using a tumor marker, serum CA 19-9, combined with an endoscopic ultrasound if the tumor marker is elevated, is more likely to detect stage 1 pancreatic cancer in a high-risk population than by using the standard means of detection.

26 Jul 2011

UC San Diego receives NHLBI 'Program of Excellence in Glycosciences' grant

Scientists at the University of California, San Diego School of Medicine have received a major 7-year, $18 million grant to begin translating emerging discoveries in the field of glycosciences into new discoveries and therapies related to heart, lung and blood diseases.

26 Jul 2011

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

Erionite in North Dakota roads may increase risk of mesothelioma

As school buses drive down the gravel roads in Dunn County, North Dakota, they stir up more than dirt. The clouds of dust left in their wake contain such high levels of the mineral erionite that those who breathe in the air every day are at an increased risk of developing mesothelioma, a type of cancer of the membranes around the lungs, new research shows.

26 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Women & Infants creates fully integrated center for high-risk pregnancy

Every pregnancy deserves special treatment. But when a woman with a normal pregnancy has a complication or a woman with a medical issue becomes pregnant, she needs highly specialized care.

26 Jul 2011

CRI announces new changes to cancer research funding programs

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today new changes and additions to its research funding programs.

26 Jul 2011

BioSante second quarter net loss increases to $15.0 million

BioSante Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2011.

26 Jul 2011

Adaptimmune announces opening of pilot clinical trial in synovial sarcoma

Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.

25 Jul 2011

Affordable cell transfer therapy for cancers

One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.

25 Jul 2011

Fluoride supplements neither safe or effective

Sodium fluoride supplements "have not been found by FDA to be safe or effective," according to the U.S. National Library of Medicine's website, reports the New York State Coalition Opposed to Fluoridation, Inc..

25 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011